3 stories mentioning AKTSUpdated 30d ago
Every FINWIRES story that references AKTS, newest first.
Shulamit Ron-Bigger, Chief Operating Officer, on July 08, 2026, sold 50,000 common shares in Aktis Oncology (AKTS) for $1,387,558.SEC Filing:https://www.sec.gov/Archives/edgar/data/2035832/000119312526300163/xslF345X05/ownership.xml
Akos Czibere, Chief Medical Officer, on July 08, 2026, sold 50,000 common shares in Aktis Oncology (AKTS) for $1,388,701.SEC Filing:https://www.sec.gov/Archives/edgar/data/2035832/000119312526300162/xslF345X05/ownership.xml
Aktis Oncology, Inc. (AKTS) has an average rating of buy and mean price target of $32.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
